Spyre Therapeutics to Participate in Upcoming Investor Conference

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE), a clinical-stage biotech company focused on Inflammatory Bowel Disease (IBD) treatment, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. The company's management will engage in a fireside chat on Wednesday, September 18, 2024, at 12:00 p.m. Eastern time.

Spyre Therapeutics specializes in antibody engineering, rational therapeutic combinations, and precision medicine approaches to improve IBD treatment efficacy and convenience. Investors and interested parties can access a webcast replay of the fireside chat on the company's investor events website for 90 days following the event.

News Market Reaction

+2.80%

1 alert

+2.80% News Effect

On the day this news was published, SYRE gained 2.80%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in a fireside chat and investor meetings at the Stifel 2024 Virtual Immunology and Inflammation Summit. Details of the fireside are as follows:

• Wednesday, September 18, 2024, at 12:00 p.m. Eastern time

A webcast replay will be available on the Spyre investor events website for 90 days following the event.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.

Follow Spyre Therapeutics on social media: @spyretx and LinkedIn

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-participate-in-upcoming-investor-conference-302244312.html

SOURCE Spyre Therapeutics, Inc.

FAQ

When is Spyre Therapeutics (SYRE) participating in the Stifel 2024 Virtual Immunology and Inflammation Summit?

Spyre Therapeutics (SYRE) is participating in the Stifel 2024 Virtual Immunology and Inflammation Summit on Wednesday, September 18, 2024, with a fireside chat scheduled for 12:00 p.m. Eastern time.

What is Spyre Therapeutics' (SYRE) focus in biotechnology?

Spyre Therapeutics (SYRE) focuses on developing treatments for Inflammatory Bowel Disease (IBD) using antibody engineering, rational therapeutic combinations, and precision medicine approaches.

How long will the webcast replay of Spyre Therapeutics' (SYRE) fireside chat be available?

The webcast replay of Spyre Therapeutics' (SYRE) fireside chat will be available on the company's investor events website for 90 days following the event.

What stock exchange is Spyre Therapeutics (SYRE) listed on?

Spyre Therapeutics (SYRE) is listed on the NASDAQ stock exchange.